Sulfanilamide in the Treatment of Experimental Streptococcic and Pneumococcic Meningitis

This is the authors' abstract. We don't add key points for this paper.

The remarkable success of sulfanilamide (para-aminobenzenesulfonamide) and its derivatives in the treatment of experimental and human infections due to beta hemolytic streptococci, and to some extent of those due to pneumococci, has given rise to the hope that these preparations will prove effective in the treatment of streptococcic and pneumococcic meningitis, especially in view of the high mortality of these diseases (as high as 97 per cent in the case of streptococcic meningitis, as shown in a recent survey by Gray¹). In February 1936 Caussé, Loiseau and Gisselbrecht²reported the recovery of a man with streptococcic meningitis of otitic origin following the intravenous and oral administration of a derivative of sulfanilamide (prontosil). The experimental work reported here was begun in January 1937, immediately after the publication of the paper by Long and Bliss³on the remarkable effects in the treatment of mice with septicemia due to beta hemolytic streptococci. Since